Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVOGet Rating) in a research report sent to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the company. TheStreet raised Aptevo Therapeutics from a d rating to a c- rating in a research report on Friday, August 26th. Piper Sandler reduced their price target on Aptevo Therapeutics from $20.00 to $13.00 in a research report on Friday, August 12th.

Aptevo Therapeutics Trading Up 1.4 %

APVO stock opened at $2.97 on Monday. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.12. The business’s 50-day moving average is $3.03 and its two-hundred day moving average is $3.71. Aptevo Therapeutics has a 1 year low of $2.67 and a 1 year high of $15.33.

Institutional Investors Weigh In On Aptevo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cantor Fitzgerald L. P. acquired a new stake in shares of Aptevo Therapeutics during the 3rd quarter worth about $406,000. Citadel Advisors LLC acquired a new stake in shares of Aptevo Therapeutics during the 3rd quarter worth about $51,000. Virtu Financial LLC raised its position in shares of Aptevo Therapeutics by 122.6% during the 3rd quarter. Virtu Financial LLC now owns 28,421 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 15,653 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Aptevo Therapeutics by 18.7% during the 2nd quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Aptevo Therapeutics by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock worth $1,414,000 after buying an additional 16,337 shares during the last quarter. Institutional investors and hedge funds own 15.63% of the company’s stock.

Aptevo Therapeutics Company Profile

(Get Rating)

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.

Read More

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.